AnaptysBio, Inc. (NASDAQ:ANAB) Shares Sold by State Board of Administration of Florida Retirement System

State Board of Administration of Florida Retirement System decreased its holdings in AnaptysBio, Inc. (NASDAQ:ANAB – Get Rating) by 13.9% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 8,426 shares of the biotechnology company’s stock after selling 1,360 shares during the quarter. State Board of Administration of Florida Retirement System’s holdings in AnaptysBio were worth $261,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of the business. Point72 Asset Management L.P. lifted its stake in shares of AnaptysBio by 196.6% in the third quarter. Point72 Asset Management L.P. now owns 2,526,200 shares of the biotechnology company’s stock worth $64,443,000 after acquiring an additional 1,674,400 shares in the last quarter. Federated Hermes Inc. increased its holdings in AnaptysBio by 3.0% in the third quarter. Federated Hermes Inc. now owns 2,372,923 shares of the biotechnology company’s stock valued at $60,533,000 after buying an additional 68,826 shares during the last quarter. Vanguard Group Inc. increased its holdings in AnaptysBio by 0.8% in the third quarter. Vanguard Group Inc. now owns 1,745,108 shares of the biotechnology company’s stock valued at $44,518,000 after buying an additional 14,638 shares during the last quarter. State Street Corp increased its holdings in AnaptysBio by 10.0% in the third quarter. State Street Corp now owns 1,271,727 shares of the biotechnology company’s stock valued at $32,442,000 after buying an additional 115,846 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in AnaptysBio by 11.0% in the first quarter. Dimensional Fund Advisors LP now owns 891,851 shares of the biotechnology company’s stock valued at $22,064,000 after buying an additional 88,457 shares during the last quarter.

AnaptysBio Stock Performance

Shares of NASDAQ:ANAB opened at $19.13 on Monday. The stock has a fifty day moving average of $21.35 and a 200-day moving average of $24.94. AnaptysBio, Inc. has a one year low of $18.03 and a one year high of $32.44. The company has a market capitalization of $506.75 million, a PE ratio of -3.95 and a beta of -0.16.

AnaptysBio (NASDAQ:ANAB – Get Rating) last posted its quarterly earnings results on Wednesday, March 1st. The biotechnology company reported ($0.93) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.01). AnaptysBio had a negative return on equity of 52.83% and a negative net margin of 1,278.87%. The company had revenue of $6.81 million during the quarter, compared to analyst estimates of $8.20 million. As a group, research analysts forecast that AnaptysBio, Inc. will post -5.89 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts recently weighed in on the company. Guggenheim boosted their price objective on AnaptysBio from $44.00 to $45.00 in a report on Friday, May 12th. JPMorgan Chase & Co. lowered their target price on AnaptysBio from $32.00 to $31.00 and set an “underweight” rating for the company in a report on Wednesday, April 12th. TD Cowen initiated coverage on AnaptysBio in a report on Thursday. They issued an “outperform” rating for the company. Finally, StockNews.com initiated coverage on AnaptysBio in a report on Thursday. They issued a “hold” rating for the company. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $34.83.

AnaptysBio Company Profile

(Get Rating)

AnaptysBio, Inc is a clinical stage biotechnology company. engages in the development of antibody product candidates. Its products pipeline include ANB030, ANB030, and Imsidolimab. It also offers SHM platform that replicate the natural process of somatic hypermutation embedded within the human immune system to rapidly develop a diverse range of therapeutic-grade antibodies in vitro.